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Psoriasis is a chronic, relapsing-remitting inflam-
matory disorder mediated by effector T cells, 
including CD4+ and CD8+  and  T cells 
(Lowes et al., 2007; Nestle et al., 2009). These 
T cells secrete an array of proinflammatory 
cytokines, including tumor necrosis factor- 
(TNF), interferon- (IFN-), IL-17, and IL-22, 
to stimulate proliferation of keratinocytes and 
recruit inflammatory cells (Di Meglio et al., 
2011; Lowes et al., 2007). Notably,  T cells 
appear to be crucial in the chronic-relapsing 
phase of the disease, where these cells become 
resident in the skin, presumably as memory 
T cells dependent on IL-15 and other homeo-
static cytokines (Boyman et al., 2007). Upon in-
duction of a psoriatic lesion, CD8+ T cells, 
notably 11 integrin+ cells, home to the epi-
dermis and correlate with epidermal thickening 
(acanthosis) and elongation of dermal papillae 
(papillomatosis), leading to enhanced interdigi-
tation of epidermis and dermis (Boyman et al., 
2004; Conrad et al., 2007). As for  T cells, the 
involvement of these cells has recently been im-
plicated in the pathogenesis of psoriasis (Laggner 
et al., 2011), especially during the early stages of 
psoriasiform skin inflammation in mouse mod-
els (Cai et al., 2011; Pantelyushin et al., 2012).
Furthermore, DCs appear to be involved 
very early in the pathogenesis of psoriasis by 
producing type I IFNs (Nestle et al., 2005). Inter-
estingly, treatment with imiquimod (IMQ), an 
agonist of Toll-like receptors (TLR) 7 and 8, can 
stimulate DCs to produce type I IFNs, and thus 
exacerbate psoriasis in patients (Gilliet et al., 2004). 
Moreover, treatment of normal mice with IMQ 
results in psoriasiform skin inflammation, which is 
characterized by epidermal thickening and inter-
digitation of epidermis and dermis, thus resem-
bling papillomatosis (van der Fits et al., 2009). 
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Stromal cells at epithelial surfaces contribute to innate immunity by sensing environmental 
danger signals and producing proinflammatory cytokines. However, the role of stromal cells 
in controlling local inflammation is unknown. We show that endogenous soluble IL-15 
receptor  (IL-15R) derived from epidermal stroma, notably keratinocytes, protects 
against dendritic cell/IL-15-mediated, T cell-driven skin inflammation in vivo, and is  
relevant to human psoriasis. Selective lack of IL-15R on stromal epidermal cells exacer-
bated psoriasiform inflammation in animals. Epidermal IL-15R was shed by keratinocytes 
via proteolytic cleavage by matrix metalloproteinases upon stimulation with proinflamma-
tory cytokines to counteract IL-15–induced proliferation of IL-17+  and  T cells and 
production of TNF, IL-23, IL-17, and IL-22 during skin inflammation. Notably, administra-
tion of soluble IL-15R was able to repress secretion of IL-1, IL-6, and TNF by keratino-
cytes, dampen expansion of IL-17+  and  T cells in vivo, and prevent psoriasis in two 
mouse models, including human xenograft AGR mice. Serum levels of soluble IL-15R 
negatively correlated with disease severity, and levels rose upon successful treatment of 
psoriasis in patients. Thus, stressed epidermal stromal cells use soluble IL-15R to dampen 
chronic inflammatory skin disease.
© 2013 Bouchaud et al. This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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dermis of the treated back or ear skin compared with control 
WT mice treated with Vaseline (Fig. 1 A). Il15/ mice showed 
consistently less thickening of the IMQ-treated ears compared 
with WT, which was already evident on day 4 of IMQ appli-
cation (Fig. 1 B). On day 6, ear thickness, epidermal thickness, 
and interdigitation of epidermis and dermis of Il15/ mice 
was 35–50% lower than in WT animals (Fig. 1, C–E).
These results were in line with a previous study reporting 
the use of a mAb interfering with the binding of IL-15 to 
IL-15R, thus inhibiting IL-15R signaling and the mainte-
nance of psoriasiform inflammation in a xenograft mouse 
model (Villadsen et al., 2003). Thus, we expected to see a simi-
lar phenotype as in Il15/ mice when treating Il15ra/ mice 
with IMQ. Very surprisingly, however, Il15ra/ animals were 
not only able to develop a psoriasiform disease upon IMQ ap-
plication, but the inflammatory skin reaction was significantly 
more pronounced than in WT mice (Fig. 1 A). Ear thickness of 
IMQ-treated Il15ra/ animals was increased as early as on day 
3 (Fig. 1 B), and, on day 6 of IMQ treatment, ear thickness, 
epidermal thickness and interdigitation of epidermis and der-
mis was 75–130% higher in Il15ra/ compared with WT 
mice (Fig. 1, C–E).
Psoriasiform skin disease depends  
on IL-15 production by DCs
Immunohistochemical analysis of skin sections from WT and 
Il15ra/ animals for IL-15 revealed the presence of IL-15+ 
cells in the dermis (unpublished data). To gain insight into 
which cells produced IL-15 upon cutaneous IMQ application, 
we generated BM chimeras using WT or Il15/ BM cells 
adoptively transferred into lethally irradiated WT or Il15/ 
hosts. Upon de novo reconstitution of the immune compart-
ment and IMQ treatment, these BM chimeras showed that 
absence of IL-15 on radio-resistant host stromal cells was dis-
pensable for skin inflammation (Fig. 2, A and B). Conversely, 
selective deficiency of IL-15 on hematopoietic cells as found in 
Il15/–WT chimeras was sufficient to replicate the pheno-
type of Il15/ mice (Fig. 2, A and B).
As IMQ is a TLR7 and 8 agonist, and these TLRs are abun-
dant in DCs, we reasoned that IL-15 production by these cells 
might be crucial for IMQ-mediated psoriasiform pathology. 
Thus, selective depletion of DCs in Cd11cDtr mice receiving 
diphtheria toxin (DT) significantly reduced skin inflammation 
upon IMQ application (unpublished data), in line with a recent 
publication (Tortola et al., 2012). To exclude the possibility that 
CD11c+ DCs produced another intermediary cytokine acting 
on another cell subset to induce IL-15 production by the latter, 
we generated chimeras carrying a 1:1 mixture of Il15/ and 
Cd11cDtr BM adoptively transferred to lethally irradiated 
WT hosts. In these mice, Il15/ DCs are resistant to DT treat-
ment but unable to produce IL-15, whereas Cd11cDtr are 
the only DCs able to secrete IL-15. Upon IMQ treatment, 
mixed chimeras receiving DT showed a similar deficiency to 
develop psoriasiform inflammation (Fig. 2 C), as did Il15/ 
mice and DT-treated Cd11cDtr animals. Conversely, mixed 
Il15/–Cd11cDtr chimeras receiving PBS developed robust 
Cutaneous inflammation in the IMQ model appears to share 
many pathophysiologic pathways with (early) psoriasis plaque 
formation (Nestle et al., 2009). Hence, the immune cascade in-
volved in this IMQ-induced psoriasis model hinges on the stim-
ulation of DCs via TLR7 and 8, leading to activation of the 
IL-23IL-17 axis with stimulation of T cells capable of IL-17 
and IL-22 production (van der Fits et al., 2009; Cai et al., 2011; 
Pantelyushin et al., 2012; Tortola et al., 2012). The importance 
of IL-17 in psoriasis is further highlighted by the recent success 
of biologics targeting IL-17 in patients (Krueger, 2012; Leonardi 
et al., 2012; Papp et al., 2012).
In addition to the immune system, keratinocytes have long 
been known to produce proinflammatory cytokines, includ-
ing TNF and IL-1, thus contributing to the inflammatory 
milieu in psoriatic skin plaques (Barker et al., 1991). Moreover, 
a publication examining the expression of IL-15 and IL- 
IL-15R on keratinocytes in vitro, as well as IL-15 and IL-
15–binding sites in skin biopsies from psoriasis patients, 
suggested that keratinocytes might stimulate neighboring 
keratinocytes and immune cells by presenting IL-15 via mem-
brane-bound IL-15R to these cells (Rückert et al., 2000). 
Recently, production of the proinflammatory IL-1 family 
member IL-36 by keratinocytes has been shown to play a role 
in inducing psoriasiform inflammation in the IMQ mouse 
model (Tortola et al., 2012). Furthermore, keratinocytes are 
known to secrete different antimicrobial peptides, including 
-defensins, LL-37 cathelicidin, and S100 proteins. Some of 
these antimicrobial peptides are able to form complexes with 
self-DNA molecules, thereby leading to the activation of DCs, 
as has been shown for LL-37–DNA complexes stimulating 
plasmacytoid DCs via TLR9 engagement to produce IFN- 
(Lande et al., 2007). Moreover, antimicrobial peptides exert 
chemotactic activities toward innate and adaptive immune cells. 
Thus, keratinocytes, through the production of antimicrobial 
peptides and proinflammatory cytokines, are contributing to 
cutaneous inflammation in immune defense, as well as in pso-
riasis (Nestle et al., 2009). However, whether keratinocytes or 
other stromal cells are involved in modulating or dampening 
inflammation in the skin is unknown.
Here, we show that stromal cells, most notably keratino-
cytes in the skin, express high levels of IL-15R and release 
soluble IL-15R (sIL-15R) via proteolytic cleavage to sup-
press the inflammatory response in murine and human psoria-
sis. These data reveal a crucial role for stroma-derived sIL-15R 
in counter-regulating inflammation in this common chronic 
inflammatory disorder.
RESULTS
Opposing effects of IL-15 and IL-15R  
in psoriasiform skin inflammation
IL-15 can induce the production of proinflammatory cyto-
kines involved in the pathogenesis of psoriasis (McInnes and 
Liew, 1998). Hence, it was not surprising that administration 
of IMQ to Il15/ mice failed to induce a psoriasiform skin 
pathology, in contrast to WT mice, which showed marked 
thickening of epidermis and interdigitation of epidermis and 
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(Fig. 2, E and F). This was not caused by the persistence of 
radio-resistant skin DCs expressing lower CD11c levels, in-
cluding Langerhans cells, the latter of which have been shown 
to resist high-dose irradiation (Merad et al., 2002). Thus, upon 
IMQ treatment, Il15ra/–Cd11cDtr chimeras receiving DT 
showed an inflammatory skin response similar to that seen 
in control chimeras receiving PBS (Fig. 2 G). Moreover, 
Langerin-Dtr (LangDtr) animals treated with DT were indistin-
guishable from PBS-treated LangDtr (Fig. 2 H), suggesting that 
Langerhans cells were not implicated in IMQ-mediated psori-
asiform skin pathology, neither in the IL-15–induced inflam-
mation nor in the IL-15R-mediated dampening of disease.
Keratinocytes express high surface IL-15R  
and release IL-15R upon stimulation
The aforementioned results suggested that stromal skin cells 
expressed significant levels of IL-15R to dampen IL-15– 
induced cutaneous inflammation. We assessed IL-15R  
ear thickening (Fig. 2 C), which was indistinguishable from 
WT–WT chimeras (Fig. 2, A and B), suggesting that IL-15 pro-
duction by roughly half of CD11c+ DCs was sufficient to in-
duce inflammatory skin disease. Further evidence for a crucial 
role of DCs producing IL-15 in this model came from DT-
treated Cd11cDtr mice receiving intradermal injection of BM-
derived DCs (BMDCs) from either WT or Il15/ mice. Upon 
IMQ treatment, only WT and not Il15/ BMDCs were able 
to induce a level of psoriasiform pathology (Fig. 2 D), which 
was comparable to IMQ-treated WT mice.
IL-15R expression by stromal cells  
dampens psoriasiform inflammation
Similar to the aforementioned experiments, we generated 
BM chimeras to investigate the cellular source of IL-15R. 
Interestingly, selective absence of IL-15R on radio-resistant 
cells in WT-Il15ra/ chimeras nicely replicated the exagger-
ated inflammatory skin response found in Il15ra/ mice 
Figure 1. Opposing effects of IL-15 and 
IL-15R in psoriasiform skin inflamma-
tion. WT, Il15/, and Il15ra/ mice were 
treated for six consecutive days with IMQ 
cream on their shaved back skin or right ear, 
whereas WT animals receiving Vaseline served 
as controls. (A) Representative hematoxylin-
eosin staining is presented of the back skin (top) 
and ear (bottom) of indicated mice on day 6. 
Bars, 100 µm. (B and C) The difference in ear 
thickness in micrometers between IMQ-treated 
and control (Vaseline)-treated animals, as deter-
mined daily (B) or on day 6 (C). Symbols repre-
sent mean difference in ear thickness ± SD  
for three to six mice per group. (D and E)  
Shown are (interfollicular) epidermal thickness 
(D) and ratio of maximal/minimal epidermal 
thickness (E). Data are representative of four 
independent experiments. P-values were deter-
mined using one-way ANOVA; *, P < 0.01;  
**, P < 0.001; ***, P < 0.0001.
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cells from skin plaques of psoriasis patients (Fig. 3 C, bottom). 
Although keratinocytes from skin plaques of psoriasis pa-
tients showed a tendency toward higher expression levels of 
cell surface IL-15R compared with keratinocytes from 
healthy individuals, upon subtraction of background stain-
ing, IL-15R levels were not significantly different be-
tween these groups (Fig. 3 D).
In primary normal human keratinocyte cultures, stimu-
lation with proinflammatory cytokines, including IL-1, 
IFN-, IFN-, and TNF, induced the release of soluble IL-
15R (sIL-15R) into the supernatant (Fig. 4, A and B). 
Similar results were obtained using primary murine kera-
tinocytes and human keratinocyte cell lines (unpublished 
data). Interestingly, the secretion of sIL-15R by human 
protein levels in single-cell suspensions of murine total skin 
using flow cytometry. Upon gating on immune lineage- 
negative (nonimmune) cells, there was a clear population of 
cells expressing high levels of IL-15R, which was present in 
the epidermal, but not dermal, fraction (Fig. 3 A, left; and not 
depicted). Strikingly, this IL-15Rhigh stromal cell subset was 
>95% positive for the keratinocyte-specific marker (cyto-) 
keratin-19 (Fig. 3 A, right). Isotype-matched control staining 
of WT murine keratinocytes gave only background signals, 
comparable to IL-15R staining of Il15ra/ murine kera-
tinocytes (Fig. 3 B).
Similar to murine cells, keratin-19+ epidermal cells obtained 
from healthy human individuals also expressed significant 
IL-15R levels (Fig. 3 C, top), as was the case for keratin-19+ 
Figure 2. IL-15R expression by stromal 
cells dampens DC-IL-15-mediated psoria-
siform skin inflammation. (A and B) BM 
chimeras were generated using WT donor BM 
adoptively transferred to lethally irradiated 
WT (WT:WT) or Il15/ (WT:Il15/) hosts, or 
by transferring Il15/ BM to lethally irradiated 
WT (Il15/:WT) or Il15/ (Il15/:Il15/) 
mice, followed by treatment for 6 consecutive 
days with IMQ cream on their right ear. 
Shown is the difference in ear thickness as in 
Fig. 1 B, either determined daily (A) or on day 
6 (B). (C) Chimeras were generated using a 1:1 
mixture of Il15/ and Cd11cDtr BM adop-
tively transferred to lethally irradiated WT 
hosts. After reconstitution, mice received 
either PBS (black line) or DT (blue line), fol-
lowed by treatment and assessment as in A. 
(D) Cd11cDtr animals, injected with DT, re-
ceived 1 d before IMQ treatment intradermal 
injection of 106 BMDC from either WT or 
Il15/ mice, followed by treatment and as-
sessment as in B. (E and F) Chimeras were 
generated using WT donor BM adoptively 
transferred to lethally irradiated WT (WT:WT) 
or Il15ra/ (WT:Il15ra/) hosts, or by trans-
ferring Il15ra/ BM to lethally irradiated WT 
(Il15ra/:WT) or Il15ra/ (Il15ra/:Il15ra/) 
mice, followed by treatment and evaluation as 
in A and B. (G) BM chimeras, generated using 
Il15ra/ BM adoptively transferred to  
lethally irradiated Cd11cDtr mice, received 
either PBS or DT, followed by treatment and 
evaluation as in B. (H) LangDtr mice received 
either PBS or DT, followed by treatment and 
assessment as in A. Symbols represent mean 
difference in ear thickness ± SD for two to 
four mice per group. Data are representative 
of two to three independent experiments.  
P-values were determined using one-way 
ANOVA; ns, not significant; ***, P < 0.0001.
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was able to correct the GM6001-mediated exacerbation 
(Fig. 4 C). Moreover, there was no evidence of increased al-
ternative splicing and generation of IL-15R lacking the 
transmembrane part (tm) encoded by exon 6 (Dubois et al., 
1999), as shown by reverse transcription polymerase chain 
reaction using specific primers for full-length and tm 
IL-15R (Fig. 4 D).
keratinocytes upon stimulation with the aforementioned cyto-
kines was almost absent in the presence of the matrix metal-
loproteinase (MMP) inhibitor GM6001 (Fig. 4 B). In line 
with these in vitro data, administration of GM6001 to WT 
mice receiving topical IMQ exacerbated cutaneous inflam-
mation, in comparison to IMQ-treated WT mice receiving 
PBS, whereas co-administration of recombinant sIL-15R 
Figure 3. Primary human and mouse keratinocytes 
express high levels of surface IL-15R. (A) Primary epi-
dermal skin cells from WT mice were analyzed by flow cy-
tometry. Shown are dot plot profiles of side scatter (SSC-H) 
versus IL-15R expression on CD45 CD3 CD11b CD11c 
CD207 MHC class II nonimmune cells, as well as histo-
grams of isotype-matched control staining (gray shaded 
area) versus (cyto-) keratin 19 expression (solid line) on 
gated IL-15Rhigh nonimmune epidermal cells. (B) Mean 
fluorescence intensity (MFI) of surface IL-15R on keratin-
19+ epidermal cells was determined by flow cytometry using 
skin from WT and Il15ra/ mice; IgG designates isotype-
matched control staining. (C and D) Surface IL-15R expres-
sion on keratin-19+ human epidermal cells was determined 
by flow cytometry using skin from healthy subjects (n = 10) 
versus psoriasis patients (n = 10). Shown are histograms of 
surface IL-15R expression (solid line) versus isotype-
matched control staining (gray shaded area) in healthy 
(C, top) and psoriasis (C, bottom), as well as MFI values, in-
cluding mean ± SD, of these groups (D). Data are representa-
tive of three independent experiments. P-values were 
determined using one-way ANOVA; ns, not significant.
Figure 4. Release of soluble IL-15R depends 
on proteolytic cleavage by MMPs, rather than 
alternative splicing of IL-15R. (A) Primary kera-
tinocytes from healthy subjects were stimulated 
using PBS, IL-1, IFN-, and TNF, and supernatant 
was collected at different time points for measuring 
levels of soluble IL-15R (sIL-15R). (B) Primary 
human keratinocytes were treated as in A using 
PBS, IL-1, IFN-, IFN-, IFN-, and TNF, without 
or with the MMP inhibitor GM6001, followed by 
determining levels of sIL-15R in the supernatant  
2 h later. (C) WT mice received IMQ cream on their 
right ear for 6 consecutive days, along with intra-
peritoneal injections of either PBS, GM6001, sIL-
15R, or GM6001 plus sIL-15R. Shown is the 
difference in ear thickness as in Fig. 1 C determined 
on day 6. (D) WT mice were treated using Vaseline 
(Ctrl) or IMQ on their right ear for 6 consecutive 
days, followed by sacrificing mice, harvesting the 
right ears for mRNA extraction, and performing RT-
PCR for full-length IL-15R (around 800 bp) versus 
IL-15R lacking the transmembrane domain (tm) 
due to alternative splicing (around 500 bp). Data are 
representative of two to three independent experi-
ments. P-values were determined using one-way 
ANOVA; *, P < 0.01; **, P < 0.001.
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sIL-15R did not develop any typical morphological signs of 
psoriasis, and, accordingly, the acanthosis and papillomatosis 
indices remained low (Fig. 6, A and B).
Similar to AGR129 mice, treatment with sIL-15R was 
also efficacious in the IMQ model of psoriasiform disease. Thus, 
WT animals receiving sIL-15R resembled Il15/ mice in 
that development of cutaneous inflammation and thickening 
upon IMQ application was significantly blunted, correspond-
ing to only 35% of the increase in thickness compared with WT 
controls (Fig. 6, C and D). Interestingly, administration of sIL-
15R to Il15ra/ animals controlled the aberrant skin inflam-
mation in these mice (Fig. 6, C and D).
To gain insight into the target cells of IL-15 and to rule 
out the possibility that sIL-15R associates with soluble 
IL-15 to form agonistic complexes that stimulate T cells and 
keratinocytes (Rückert et al., 2000; Rubinstein et al., 2006; 
Stoklasek et al., 2006), we stimulated primary keratinocytes 
and T cells using IL-15 without or with addition of sIL-
15R. Paralleling the aforementioned results, production of 
IL-1, IL-6, and TNF by IL-15–stimulated primary human 
and murine keratinocytes was significantly reduced when 
sIL-15R was added to the cultures (Fig. 6 E; and not de-
picted). Moreover, culturing of total skin cells with IL-15 
led to an increase of IL-17–producing  and  T cells, 
which was significantly reduced when sIL-15R was co-
administered (Fig. 6, F and G). Notably, skin-resident T cells 
expressed IL-15 receptors, and levels of IL-15R (CD122) 
and c on these cells did not change upon application of IMQ 
(unpublished data).
Opposing regulation of IL-15 and sIL-15R  
in psoriasis patients influences T cell proliferation
Our data on IL-15R expression on human keratinocytes 
and the role of sIL-15R in dampening psoriasiform disease 
in two relevant animal models suggested that the IL-15 
IL-15R system might also play an important role in psoria-
sis patients. To this end, we assessed IL-15 and sIL-15R  
levels in serum of psoriasis patients (n = 52) using ultrasensi-
tive radio-immunoassays. IL-15 levels steadily rose with in-
creasing disease severity, as reflected by the psoriasis area and 
severity index, following a linear correlation (Fig. 7 A; r = 
0.72; Spearman test, P < 0.0001). Strikingly, however, sIL-
15R showed a completely opposite trend. Thus, serum sIL-
15R levels decreased with higher PASI scores, leading to a 
negative linear correlation (Fig. 7 B; r = 0.49; Spearman 
test, P < 0.0001).
The opposing regulation of IL-15 and sIL-15R could 
indicate interindividual variability. Thus, we measured these 
parameters in individual psoriasis patients before and after anti-
psoriatic treatment (n = 17). As expected, antipsoriatic therapy 
led to a marked reduction of disease severity in most of 
the patients as measured by PASI, which was paralleled by a 
significant decrease of serum IL-15 to background levels in 
the patients (Fig. 7 C, left and middle). In sharp contrast to 
IL-15, serum levels of sIL-15R rose 2–12-fold after treat-
ment (Fig. 7 C, right).
Collectively, these data show that murine and human ker-
atinocytes express significant levels of IL-15R, both during 
homeostasis and inflammation and that upon stimulation 
with proinflammatory cytokines, keratinocytes are able to re-
lease sIL-15R via proteolytic cleavage by MMPs.
IL-15 drives T cell expansion and production  
of proinflammatory cytokines
As previously mentioned, IL-15 is able to induce the pro-
duction of different proinflammatory cytokines implicated 
in the pathogenesis of psoriasis (McInnes and Liew, 1998). 
Moreover, IL-15 is a common  chain (c) cytokine and, 
similar to other c cytokine members, IL-15 is involved in 
the survival and maintenance of T cells, especially memory 
CD8+ and, to a lesser extent, memory CD4+ T cells (Boyman 
et al., 2012).
Paralleling the degree of psoriasiform inflammation, 
Il15ra/ animals showed the strongest expansion of CD3+  
T cells upon IMQ treatment, followed by WT and Il15/ 
mice (Fig. 5, A and B). The increase in cell counts and percent-
ages was most notable for CD8+ T cells, which were over 5-fold 
more prominent in Il15ra/ animals compared with WT and 
over 20-fold in comparison to Il15/ mice. CD4+ T cells were 
also increased in IMQ-treated Il15ra/ animals, being twice as 
abundant as in WT and three times more than in Il15/ mice.
As for effector cytokines, the mRNA levels of IL-15 and 
TNF, as well as IL-23p19, IL-17, and IL-22, were 3–6-fold 
higher in Il15ra/ animals compared with WT mice upon 
IMQ application for 3 d (Fig. 5 C). Conversely, levels of these 
cytokines were at least twofold lower in Il15/ mice com-
pared with WT (Fig. 5 C).
In line with these expression data, IL-17–producing  
and  T cells were increased in Il15ra/ mice in compari-
son to WT, whereas Il15/ animals had significantly lower 
counts of IL-17+ skin T cells (Fig. 5, D and E).
Administration of sIL-15R inhibits human  
and murine psoriasiform disease
Our data showing that IL-15R derived from stromal cells, 
most notably from keratinocytes, dampens IMQ-induced 
skin disease suggested that administration of IL-15R mol-
ecules might improve psoriasiform inflammation. As mu-
rine skin lacks distinct features of human skin, and thus 
cannot entirely mimic psoriasis, we expanded our findings 
in the IMQ mouse model by taking advantage of our well-
established human xenograft psoriasis model (Boyman 
et al., 2004). As expected, transplantation of symptomless pre-
psoriatic skin grafts from a psoriasis patient onto immuno-
deficient AGR129 mice induced the skin grafts to spontaneously 
develop a fully-fledged psoriatic phenotype within 6–8 wk. 
Thus, human xenografts of PBS-treated control animals 
showed characteristic features of psoriasis, including acantho-
sis, papillomatosis, loss of granular cell layer, and dense infil-
trates of mononuclear cells in the dermis and epidermis 
representing immune cells (Fig. 6, A and B). In sharp contrast 
to PBS controls, xenografts of AGR129 mice treated with 
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with PASI scores of 5 and lower almost completely inhib-
ited IL-15–mediated proliferation of CTLL-2 cells, whereas 
serum specimens of patients with increasing PASI scores 
progressively lost the ability to block IL-15–mediated T cell 
stimulation (Fig. 7 E).
These data establish in psoriasis patients that disease sever-
ity and IL-15 correlate directly with each other, whereas 
concomitant regulation of biologically active sIL-15R fol-
lows an opposite trend.
To assess the biological activity of serum IL-15 and 
sIL-15R, we performed direct ex vivo proliferation assays 
using the IL-15–sensitive T cell line CTLL-2. Direct cultur-
ing of CTLL-2 cells with sera led to proliferation of the 
cells, which was most prominent when using sera from pa-
tients with higher PASI scores (Fig. 7 D). The biological 
property of sIL-15R was assessed by culturing CTLL-2 
cells with a fixed concentration of recombinant human IL-15, 
followed by addition of sera. Samples of psoriasis patients 
Figure 5. IL-15 drives T cell expansion and production of proinflammatory cytokines. (A and B) WT, Il15/, and Il15ra/ mice were treated for 
6 consecutive days with IMQ cream on their right ear. Epidermal skin cells were isolated and analyzed by flow cytometry for T cell subsets. Shown are 
absolute numbers (A) and dot plots (B) of CD8+ (open bars) and CD4+ (filled bars) CD3+ T cells in indicated animals. (C) mRNA levels of IL-15, IL-15R, TNF, 
IL-23p19, IL-17, and IL-22 were measured by quantitative RT-PCR in ears of WT, Il15/, and Il15ra/ mice treated for 3 consecutive days with IMQ. 
Shown is fold increase in mRNA normalized to ribosomal protein L27 versus control skin of WT mice. Data are displayed as mean ± SD. (D and E) WT, 
Il15/, and Il15ra/ mice received IMQ for 3 d, followed by direct ex vivo analysis of intracellular IL-17 production in  (D) and  T cells (E). Data are 
pooled results from two to four independent experiments. P-values were determined using one-way ANOVA; *, P < 0.01; **, P < 0.001; ***, P < 0.0001.
 o
n
 D
ecem
ber 24, 2013
jem.rupress.org
D
ow
nloaded from
 
Published September 9, 2013
2112 Stromal IL-15R dampens skin inflammation | Bouchaud et al.
Figure 6. Administration of sIL-15R inhibits human and murine psoriasiform disease. (A and B) Development of a psoriatic phenotype in 
symptomless prepsoriatic human skin transplantated onto AGR129 mice is prevented by injection of sIL-15R. Shown is representative hematoxy-
lin-eosin staining at low- (left) and and high-power (right) magnification (A), and acanthosis (B, top), and papillomatosis index (B, bottom) of the 
human skin grafts 6 wk after transplantation onto AGR129 mice receiving either PBS or sIL-15R. Bars, 50 µm. Data are representative of four 
mice per group. (C and D) WT, WT receiving sIL-15R, and Il15ra/ mice injected with sIL-15R were treated for 6 consecutive days with IMQ 
cream on their right ear. Mice were assessed as in Fig. 1 (B and C). (E) Primary human keratinocytes were stimulated with either PBS, IL-15, IL-15 
plus sIL-15R, or sIL-15R, followed by analysis of IL-1, IL-6, and TNF by ELISA. (F and G) Epidermal skin cells from WT mice were stimulated 
with either PBS, IL-15, IL-15 plus sIL-15R, or sIL-15R, followed by analysis using flow cytometry. Shown are percentages of IL-17–producing 
CD3+  (F) and  T cells (G) as mean ± SD. Data are representative of two independent experiments. P-values were determined using one-way 
ANOVA; *, P < 0.01; **, P < 0.001; ***, P < 0.0001.
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of memory CD8+ and NK cells in mice (Rubinstein et al., 
2006; Stoklasek et al., 2006). Conversely, injection of recombi-
nant sIL-15R is able to reduce collagen-induced arthritis 
(Ruchatz et al., 1998), and to inhibit homeostasis of memory 
CD8+ and NK cells in vivo (Khan et al., 2002; Nguyen et al., 
2002). The implications from these data are that sIL-15R is a 
potent regulator of IL-15 activity, acting as an agonist or antag-
onist. However, there is no evidence as to whether endogenous, 
natural (i.e., not recombinant) sIL-15R is able to modulate 
IL-15 signaling in vivo. The data presented in this study dem-
onstrate for the first time that endogenous sIL-15R is impli-
cated in reducing cutaneous inflammation in psoriasis, both in 
mice and men.
We show that during psoriasiform inflammation, abundant 
production of IL-15 by DCs causes the activation of  and  
effector T cells. These T cells need only to express dimeric IL-
15R to efficiently bind IL-15 and signal, as demonstrated by 
experiments using Il15ra/–WT mixed BM chimeras lacking 
membrane-bound IL-15R on both T cells and DCs. Hence, 
Il15ra/–WT chimeras show identical inflammatory responses 
as WT–WT chimeras. Notably, the dimeric IL-15R pos-
sesses an affinity for IL-15 of 109 M, and thus is able to 
avidly bind IL-15, even in the absence of IL-15R in cis or in 
trans (Waldmann and Tagaya, 1999). However, sIL-15R has an 
DISCUSSION
Our data demonstrate that during inflammation availability of 
IL-15 is regulated by proteolytic cleavage and shedding of 
IL-15R from epidermal stromal cells, unveiling an unex-
pected role of tissue-derived sIL-15R in psoriasis. Although 
the crucial function of IL-15R in the IL-15 system is well 
known, the role of endogenous sIL-15R in IL-15 homeo-
stasis has remained elusive. Hence, Il15/ and Il15ra/ mice 
both lack memory CD8+ T cells and NK cells (Lodolce et al., 
1998; Kennedy et al., 2000; Boyman et al., 2012), implying 
that IL-15 depends on IL-15R for signaling. This is explained 
by the fact that IL-15 binds cells expressing surface IL-15R 
together with CD122 and c. In addition to this classical cis in-
teraction, DCs can produce and present IL-15 in trans via 
membrane-bound IL-15R to neighboring CD8+ and NK 
cells expressing dimeric IL-15R, consisting of CD122 and 
c (Dubois et al., 2002; Schluns et al., 2004; Burkett et al., 
2004). Thus, binding and presentation of IL-15 by membrane-
bound IL-15R delivers a stimulatory signal.
Moreover, IL-15R also exists in a soluble form and, un-
like membrane-bound IL-15R, sIL-15R can act either as 
an agonist or antagonist of IL-15 in vivo. Thus, recombinant 
sIL-15R combined with recombinant IL-15, thereby form-
ing IL-15sIL-15R complexes, can cause massive expansion 
Figure 7. Opposing regulation of IL-15 
and sIL-15R in psoriasis patients influ-
ences T cell proliferation. (A and B) IL-15 
and sIL-15R were assessed in the serum  
of psoriasis patients (n = 52) using specific 
radio-immunoassays. Shown are serum levels 
of IL-15 (A) and sIL-15R (B) versus the PASI, 
with each dot representing a patient, the blue 
line corresponding to the Pearson correlation 
and the dashed lines to the 95% confidence 
interval; r (IL-15) = 0.72; Spearman test, P < 
0.0001; r (IL-15R) = 0.49; Spearman test, P <  
0.0001. (C) Individual psoriasis patients (n = 17) 
were seen before and after antipsoriatic treat-
ment (see Materials and methods), at which 
time-points PASI (left) and serum IL-15 (middle) 
and sIL-15R levels (right) were determined. 
Statistic comparison using a Mann-Whitney  
U test of the groups before and after resulted 
in P-values of 0.0034 (**) and 0.0001 (***).  
(D and E) Proliferation of CTLL-2 T cells incu-
bated with either serum of psoriasis patients 
(D) or with a fixed saturating concentration of 
recombinant human IL-15 along with serum 
of psoriasis patients (E) was assessed by in-
corporation of [3H]thymidine. Shown is the 
Pearson correlation (blue line) with 95% con-
fidence interval (dashed lines) of PASI versus 
proliferation (D; r = 0.69; Spearman test, P < 
0.0001) and inhibition (E; r = 0.76; Spear-
man test, P < 0.0001), respectively. Data are 
pooled results of two independent experi-
ments in triplicates.
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IL-15R and production of IL-15R molecules lacking the 
transmembrane domain, was not increased during psoriasi-
form inflammation. These findings show that inflammation-
mediated expression of MMPs provides a negative feedback 
via the release of sIL-15R to dampen IL-15–driven pathol-
ogy. Moreover, the data illustrate that stromal cells, including 
keratinocytes, are not only able to amplify inflammation via 
the production of proinflammatory cytokines and antimicro-
bial peptides but they also possess the capacity to control an 
inflammatory response, at least to a certain degree. Thus, in 
psoriasis patients, serum sIL-15R is presumably able to buf-
fer systemic IL-15 levels in mild disease. However, with in-
creasing severity of psoriasis, the rise of IL-15 is not accompanied 
by a release of sIL-15R. This failure to further increase the 
levels of sIL-15R could result from limited bioavailability of 
stroma-derived sIL-15R, perhaps due to exhaustion or from 
a defect in shedding.
Our study highlights the importance of tissue-specific 
mechanisms in regulating availability of cytokines by show-
ing the crucial role of the IL-15IL-15R system in chronic 
inflammation. Manipulating IL-15 signaling, by provision of 
recombinant sIL-15R or use of neutralizing antibodies spe-
cific for IL-15, holds the promise to interfere with the vicious 
cycle driving chronic inflammatory disorders, including pso-
riasis, inflammatory bowel disease, and rheumatoid arthritis 
(Baslund et al., 2005).
MATERIALS AND METHODS
Mice and human subjects. C57BL/6 (WT) and Il15ra/ mice were pur-
chased from The Jackson Laboratory, and IL-15/ animals were from 
Taconic. Mice expressing DT receptor (DTR) under control of the CD11c 
(Cd11cDtr) or the Langerin promoter (LangDtr) have been published pre-
viously (Jung et al., 2002; Kissenpfennig et al., 2005) and were purchased from 
The Jackson Laboratory or provided by B. Malissen (Centre d’Immunologie 
de Marseille-Luminy, Marseille, France), respectively. All transgenic mice 
were on a C57BL/6 background. For depletion of CD11c+ cells in Cd11cDtr 
or Langerin+ cells in LangDtr mice, animals received intraperitoneal injections 
of 200 ng DT (Sigma-Aldrich) in PBS every other day, starting 1 d before 
IMQ treatment. AGR129 mice deficient in type I and II IFN receptors in ad-
dition to being Rag2/ have been previously published (Boyman et al., 
2004). Mice were maintained under specific pathogen–free conditions and 
used at 6–8 wk of age. Animal experiments were performed in accordance 
with Swiss Federal Veterinary Office guidelines and approved by the Cantonal 
Veterinary Office in Zurich (Veterinäramt, Gesundheitsdirektion Kanton 
Zürich). Use of human samples was approved by the local ethical committee 
and informed consent was obtained from patients. 17 patients were recruited 
and seen before and after antipsoriatic treatment. The patients’ mean age was 
44.2 (±12.6) years; and the male/female ratio was 14:3; mean disease duration 
was 9.8 yr; 4 out of 17 patients had evidence of psoriatic arthritis; and on aver-
age patients had previously received 1–2 systemic treatments (range, 1 to 5). 
During this study, patients examined before and on treatment were adminis-
tered systemic fumaric acid ester, systemic methotrexate, systemic TNF-
blocking agents, or systemic p40 IL-12/-23–blocking agents.
IMQ-induced psoriasiform skin inflammation model. For induction of 
skin inflammation, mouse ears or  shaved backs were treated for 6 consecutive 
days using 60–80 mg Aldara cream containing 5% (3–4 mg) IMQ (3M Phar-
maceuticals) or Vaseline (Vifor SA). Mice were evaluated daily by measuring 
ear thickness using a digital micrometer (Mitutoyo). For treatment using sIL-
15R, mice received five consecutive intraperitoneal injections of 3 µg soluble 
affinity for IL-15 of 1011 M, which is 100-fold higher than 
the dimeric IL-15R, thus, even small concentrations of sIL-
15R are able to compete with IL-15 binding to the dimeric 
IL-15R. This notion fits well with our herein presented 
data. Moreover, as demonstrated by using WT-Il15ra/ mixed 
BM chimeras, in the absence of stromal sIL-15R, the stimu-
latory action of IL-15 on  and  effector T cells becomes 
unopposed, thus leading to an inflammatory response that is 
even more pronounced than in WT mice.
These data also highlight the role of IL-15 in driving an 
(auto-) inflammatory pathology. IL-15 boosts the production 
of proinflammatory cytokines, including TNF, by keratino-
cytes and T cells, as well as IL-17, IL-22, and IL-23 by mu-
rine  and  T cells, as shown here, and IL-17 by human 
T cells (Hoeve et al., 2006). In turn, TNF is a well-known 
driver of the inflammatory response in psoriasis (Mease et al., 
2000; Chaudhari et al., 2001; Boyman et al., 2004) and also 
enhances the production of other proinflammatory cytokines, 
including IL-15, thereby fueling a positive feedback loop. 
Moreover, IL-15 has been suggested to inhibit Fas-induced 
apoptosis of keratinocytes (Rückert et al., 2000).
In line with other studies showing that psoriasiform in-
flammation can be inhibited by blocking IL-15 signals using 
exogenous administration of an anti–IL-15 mAb (Villadsen 
et al., 2003), we demonstrate that this pathological inflamma-
tion can be dampened both in human and murine skin by in-
jecting recombinant sIL-15R in the AGR mouse model of 
psoriasis or to WT and Il15ra/ animals in the IMQ model. 
Remarkably, endogenous sIL-15R is able to exert a similar 
function as recombinant sIL-15R by depriving pathogenic 
T cells from contact with IL-15. In line with these data in 
mice, we also demonstrate that levels of sIL-15R negatively 
correlate with disease severity in psoriasis patients and that 
serum concentrations of sIL-15R rise upon successful ther-
apy. Using direct ex vivo testing of patients’ sera containing 
high titers of sIL-15R, we found that sIL-15R inhibited 
IL-15–driven T cell proliferation. Likewise, treatment of pa-
tients with Crohn’s disease using the anti-TNF mAb inflix-
imab has been shown to increase serum levels of sIL-15R, 
presumably via reverse signaling of infliximab through TNF 
receptors (Bouchaud et al., 2010), suggesting that sIL-15R 
might serve as an IL-15 antagonist also in inflammatory con-
ditions other than psoriasis. It will be interesting to perform 
subgroup analyses of larger cohorts of psoriasis patients before 
and during antipsoriatic treatment to determine whether top-
ical treatment is also able to correct the serum levels of sIL-
15R and whether some systemic therapeutics are more 
efficient than others in restoring serum sIL-15R levels.
An important point of the present study worth emphasiz-
ing is that sIL-15R is produced and shed by stromal cells, 
thus contributing to the cross-talk between stroma and im-
mune system. In our hands, IL-15R shedding was induced 
in human and murine keratinocytes upon incubation with 
different proinflammatory cytokines and was dependent on 
proteolytic cleavage by MMPs, as demonstrated by using a 
specific MMP inhibitor. Conversely, alternative splicing of 
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containing RPMI supplemented with 5% FCS and nonessential amino acids, 
2 mM L-glutamine, and 100 U/ml penicillin/streptomycin for 1 d. Sub-
sequently, nonadherent cells were cultured with DC media plus 20 ng/ml 
GM-CSF (R&D Systems) for another 5 d, followed by maturation of cells 
(using LPS overnight), harvesting, and intradermal injection into the ear of 
1 3 106 cells.
Flow cytometry. For obtaining single-cell suspensions, mouse or human 
skin was incubated in dispase (5 mg/ml) to separate epidermis from dermis. 
Epidermal cell suspensions were prepared by treating epidermis with trypsin-
EDTA. Collagenase IV, DNase I, and trypsin-EDTA were used to obtain 
dermal suspensions. Single-cell suspensions were stained according to stan-
dard protocols using PBS containing 1% FCS and 2 mM EDTA (Krieg et al., 
2010), with the following fluorochrome-conjugated mAbs (BD, unless oth-
erwise stated): anti–mouse  TCR,  TCR, CD3, CD4, CD8, CD11b, 
CD11c, CD45.2, CD207, (cyto-) keratin-19 (Dako), IL-15R, IL-17, and 
MHC class II; anti–human CD3, CD11b, CD11c, CD207, MHC class II, 
and anti–human IL-15R and (cyto-) keratin-19 (both from eBioscience). 
For intracellular IL-17 staining, mice received IMQ for 3 d, followed by 
intravenous injection of 250 µg of Brefeldin A (Sigma-Aldrich) 4 h before 
euthanization and analysis by flow cytometry. Alternatively, mouse cells 
were isolated and stimulated in vitro with 100 ng/ml recombinant human 
IL-15 without or with sIL-15R-Fc for 24 h in the presence of Golgi stop 
(BD). After cell surface staining, cells were fixed, permeabilized, and stained 
intracellularly for IL-17. Samples were harvested using a FACSCanto II (BD) 
and analyzed using FlowJo software (Tree Star).
RT-PCR. Ears were immersed in mRNAlater solution (Applied Biosystems) 
and kept at 80°C, and then homogenized using Tissue Lyser II (QIAGEN) 
and total mRNA was purified using the Fibrous Mini kit (QIAGEN). After 
reverse transcription into cDNA using the Reverse Transcription kit 
(QIAGEN), PCR was performed on a Viia7 RT-PCR detection system 
(Applied Biosystems). Full-length versus tm Il15ra mRNA was assessed 
using RT-PCR, whereas levels of all other cytokines were determined via 
quantitative RT-PCR using SYBR Green supermix (QIAGEN). The 
sequences of specific primers (from Microsynth) were as follows: Il15 forward, 
5-CATCCATCTCGTGCTACTTGTG-3; Il15 reverse, 5-GCCTCT-
GTTTTAGGGAGACCT-3; full-length Il15ra forward, 5-ATGGCCT-
CGCCGCAG-3; full-length Il15ra reverse, 5-TTAGGCTCCTGT-
GTCTTCATC-3; tm Il15ra forward, 5-ATGGCCTCGCCGCAG-3; 
tm Il15ra reverse, 5-GGACTTGTGACTGCCTGTCC-3; Il17 forward, 
5-TTGGAGGCAGACACCCACC-3; Il17 reverse, 5-GATAGCGGTCC-
TCATCCGTG-3; Il22 forward, 5-ATACATCGTCAACCGCACCTTT-3; 
Il22 reverse, 5-AGCCGGACATCTGTGTTGTTAT-3; Il23p19 forward, 
5-TATCCAGTGTGAAGATGGTTGTG-3; Il23p19 reverse, 5-CACTA-
AGGGCTCAGTCAGAGTTG-3; Tnfa forward, 5-TGTAGCCCACGT-
CGTAGCAAA-3; Tnfa reverse, 5-CTGGCACCACTAGTTGGTTGT-3. 
Gene expression was normalized using the ribosomal protein L27 (RPL27) 
housekeeping gene and data are represented as fold differences by the 2Ct 
method, with Ct = Cttarget gene  CtRpl27, and Ct = Ctinduced  Ctreference, 
as previously published (Cai et al., 2011).
Statistical analysis. Statistical analyses were done using one-way ANOVA 
with Bonferroni’s multiple comparison test, a Mann-Whitney U test, or a 
Spearman test, as indicated.
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human IL-15R-Fc (R&D Systems). The MMP inhibitor GM6001 (Merck) 
was given by intraperitoneal injections at 250 µg every day for 6 d.
AGR129 human xenograft psoriasis model. Transplantation of symp-
tomless prepsoriatic skin grafts from psoriasis patients onto immunodeficient 
AGR129 mice was performed as previously described (Boyman et al., 2004), 
leading to the spontaneous development of a fully-fledged psoriatic pheno-
type within 6–8 wk.
Histopathological and immunohistochemical analysis. Murine and 
human skin samples were snap frozen and stained using hematoxylin-eosin 
or immunohistochemistry, as previously reported (Boyman et al., 2004). 
Epidermal thickness (termed acanthosis for human skin samples) and the 
ratio of maximal/minimal epidermal thickness (termed papillomatosis for 
human skin samples) were evaluated for at least 4 mice, as previously re-
ported (Boyman et al., 2004). In murine skin samples, epidermal thickness 
was determined by measuring the thickness of the interfollicular epidermis at 
10 representative sites of the histological slide. In human skin samples, acan-
thosis was obtained by measuring the thickness of the viable epidermis at 
10 representative sites of the histological slide showing an uninterrupted epi-
dermis. Sections were analyzed using ImageScope for image acquisition 
(Aperio Technologies, Inc.).
Quantification of cytokine levels. Quantification of sIL-15R and IL-15 
was determined, as previously established (Bouchaud et al., 2010). Sandwich 
radio-immunoassays were set up using goat anti–human IL-15R or mouse 
anti–human IL-15 mAbs (R&D Systems) as capture and radio-iodinated anti–
human IL-15R (R&D Systems) or anti–human IL-15 mAbs (Diaclone) as 
tracer. Recombinant human sIL-15R (R&D Systems) and recombinant 
human IL-15 (eBioscience) served as standards. Supernatants of each well were 
collected, and the wells were washed twice with PBS. The radioactivity associated 
with the wells (bound fraction) or contained in the supernatants and washes 
(unbound fraction) was determined. The quantitative measurement of IL-1, 
IL-6, and TNF was performed using commercially available solid-phase ELISA 
kits (R&D Systems). All samples were assayed in triplicates.
Keratinocyte cultures. Primary human keratinocytes isolated from foreskin 
were cultured in 6-well plates using Keratinocyte-SFM media (Gibco) plus 
epidermal growth factor (5 ng/ml) and bovine pituitary extract (50 µg/ml) at 
60–70% confluence for 24 h at 37°C, with the addition of either PBS, IL-1 
(20 ng/ml), IFN- (100 ng/ml), IFN- (100 ng/ml), IFN- (100 ng/ml), or 
TNF (200 ng/ml), with or without GM6001 (0.2 nM). Subsequently, super-
natants were collected and centrifuged before analysis. Alternatively, murine 
primary keratinocytes or the human keratinocyte cell line HaCaT were used 
by culturing these cells in DMEM supplemented with 2 mM L-glutamine and 
10% FCS using the aforementioned stimulation conditions.
T cell proliferation. The proliferative response to serum IL-15 and sIL-
15R was measured by [3H]thymidine incorporation using the CTLL-2 cell 
line (ATCC-TIB-214) as previously described (Bouchaud et al., 2008). 
CTLL-2 cells were cultured in RPMI-1640 medium containing 8% heat-
inactivated FCS, 2 mM glutamine, and 10 ng/ml rhIL-2. Cells were main-
tained in culture medium for 3 d, washed twice, and starved for 4 h in the 
same medium without cytokine, followed by plating at 104 cells in 100 µl 
and culturing for 48 h in medium supplemented with patient serum. Cells 
were pulsed for the last 16 h with 0.5 µCi/well of [3H]thymidine, before 
harvesting onto glass fiber filters and measuring of cell-associated radioactiv-
ity using a -counter (Perkin-Elmer).
Generation of BM chimeras and BMDCs. For the generation of BM 
chimeras, recipient mice were irradiated with 950 rad, followed by intrave-
nous injection of 2–5 × 106 BM cells. 8–12 wk after BM reconstitution, 
mice were used for experiments.
BMDCs were generated by obtaining single-cell suspensions from BM 
of murine tibias and femurs, followed by culturing the cells in DC media 
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